Sangamo Therapeutics

This morning we are pleased to announce the completion of the acquisition of TxCell. #CARTreg #Immunology #celltherapy https://goo.gl/qNovXN

This morning we announced that our third quarter earnings call will take place on Thursday, November 8 at 5 pm ET. Click here for webcast details: https://goo.gl/oBKS5D

This morning we are pleased to announce the completion of the acquisition of TxCell. #CARTreg #Immunology #celltherapy https://goo.gl/qNovXN

This morning we announced that our third quarter earnings call will take place on Thursday, November 8 at 5 pm ET. Click here for webcast details: https://goo.gl/oBKS5D

This morning we are pleased to announce the completion of the acquisition of TxCell. Read more here: https://goo.gl/JqVZCi

We are excited to share our new and improved corporate website! www.sangamo.com

Earlier today we announced our participation at upcoming industry and investor conferences. Click here to read where we will be presenting: https://goo.gl/tBPbgG

A recording of today's conference call on our 16 week MPS II clinical data can be found through the following link: https://goo.gl/HxWHBF

Today we announce our 16 week clinical results, including reductions in glycosaminoglycans in our phase 1/2 trial evaluating SB-913, a zinc finger nuclease genome editing treatment for MPS II (Hunter Syndrome). #GenomeEditing #MPSII https://goo.gl/Ay8BNM

Today we announced our upcoming conference call to review SB-913, #MPSII study data and our participation at upcoming investor conferences. https://goo.gl/E3kCPx

Congratulations Alnylam Pharmaceuticals on the approval of Onpattro. A great step forward for genetic therapies!

Today we announced positive preliminary data from the phase 1/2 Alta study evaluating SB-525 #GeneTherapy for #HemophiliaA. https://goo.gl/xDqdAR

Team Sangamo at the 15th International MPS Symposium in San Diego. #MPS2018 #rarediseases #MPSsociety

This morning we announced that we are hosting our second quarter conference call on Wednesday, August 8 at 5 pm ET. https://goo.gl/hUqxeE